ArticleEuropean clinical respiratory journal2025
Airway hyperresponsiveness to mannitol in relation to inspiratory and expiratory resistance in subjects with asthma, COPD, and healthy smokers.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedCorrection.2025
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Airway hyperresponsiveness (AHR), a key feature of asthma, leads to airway narrowing in response to bronchoconstrictor stimuli. Notably, AHR is also observed in individuals with chronic obstructive pulmonary disease (COPD). The Mannitol challenge test is an indirect method to assess airway hyperresponsiveness. Objective: The primary aim of this study was to explore airway hyperresponsiveness to mannitol in subjects with asthma and COPD regarding inspiratory and expiratory resistance and reactance. A secondary aim was to investigate fractional exhaled nitric oxide (FeNO), blood eosinophils, allergen sensitization, and symptom scores concerning airway hyperresponsiveness to mannitol. Methods: The Mannitol challenge test was conducted on 292 subjects: 238 with asthma, 25 with COPD, 14 healthy smokers, and 15 healthy never-smokers. The response was assessed using both spirometry and respiratory oscillometry, with inspiratory and expiratory resistance and reactance measured separately. Results: A positive mannitol test was confirmed in 84 (35%) subjects with asthma, 13 (52%) with COPD, and 7 (50%) of healthy smokers. Subjects with asthma who had a positive mannitol test had a higher inspiratory R5 and R19 at baseline, and also greater change in both inspiratory and expiratory R5, R5-R19, and X5 (but not R19), compared to asthma subjects with a negative test. A similar tendency was seen among subjects with COPD and healthy smokers. Subjects with asthma with a positive mannitol test had more symptoms than subjects with a negative test (median 21 versus 22; Conclusion: Inspiratory resistance, as measured by respiratory oscillometry, was shown to predict hyperresponsiveness to mannitol in asthma patients. Furthermore, respiratory oscillometry revealed a significant increase in resistance, primarily in the peripheral airways, following a mannitol challenge in these subjects. Integrating resistance and reactance measurements, along with traditional spirometry may offer a more comprehensive understanding of the hyperreactive airway response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.